Design and rationale of the EMPagliflozin after Aortic Valve Replacement (EMPAVR) study: a randomized clinical trial - PubMed
7 hours ago
- #Aortic Stenosis
- #Cardiac Remodeling
- #SGLT2 Inhibitor
- The EMPAVR study is a randomized, double-blind, placebo-controlled trial investigating the effects of empagliflozin on left ventricular remodeling in patients with severe symptomatic aortic stenosis undergoing TAVI.
- Its primary outcome is the change in left ventricular mass indexed to body surface area from pre-TAVI to 6 months post-TAVI, measured via cardiac CT.
- The trial aims to determine if SGLT2 inhibition can improve post-procedural outcomes and symptomatic relief, potentially influencing treatment strategies for valvular heart disease globally.